{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T04:56:20Z","timestamp":1790571380021,"version":"4.1.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Stroke"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Clopidogrel is commonly used for secondary prevention after ischemic cerebrovascular events, but substantial interindividual variability in pharmacodynamics response has been reported. Individuals demonstrating resistance to clopidogrel face a higher likelihood of recurrent ischemic events. This study evaluated clopidogrel responsiveness among Jewish and Arab patients treated within the same regional healthcare setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This prospective cohort included 102 patients with ischemic cerebrovascular events (acute ischemic stroke or transient ischemic attack) receiving clopidogrel for secondary prevention. Patients received either a loading dose (300 in 62 patients, 600 mg in 1 patient) followed by maintenance therapy or at least 7 days of 75 mg daily maintenance dosing (\n                      <jats:italic>n<\/jats:italic>\n                      = 39) prior to blood sampling. Platelet responsiveness was measured using the vasodilator-stimulated phosphoprotein (VASP) phosphorylation assay (PLT VASP\/P2Y12, BioCytex, France). Patients were categorized according to VASP platelet reactivity index (PRI) as adequate responders (PRI &amp;lt;50%), intermediate responders (PRI 50%\u221269%), or patients with high residual platelet reactivity, operationally defined in this study as PRI \u226570%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included 102 enrolled patients, of whom 57 (55.9%) were Jewish and 45 (44.1%) were Arab. A valid VASP-PRI measurement was available for 101 patients (57 Jewish and 44 Arab); one Arab patient had no evaluable PRI measurement. Therefore, analyses of platelet reactivity were based on 101 patients The median PRI for all patients was 65.5 (49.1\u201380.3), with no statistically significant differences between Jewish and Arab (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.251). Overall, 42.6% were classified as non-responders, 29.7% as partial responders, and only 27.7% demonstrated adequate platelet inhibition. Jewish patients were significantly older than Arab patients (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.008), whereas Arab patients had a significantly higher BMI (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.019). Other demographic and clinical features were similar across groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A high proportion of patients demonstrated elevated residual platelet reactivity according to the operational PRI threshold used in this study. No statistically significant ethnic difference in PRI was detected; however, the ethnic comparison was exploratory and the study was not powered to exclude modest between-group differences. Larger prospective studies incorporating CYP2C19 genotyping and longitudinal clinical outcomes are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fstro.2026.1908099","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T04:29:23Z","timestamp":1790569763000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A prospective study evaluating clopidogrel resistance among patients with ischemic cerebrovascular events across different ethnic groups in Israel"],"prefix":"10.3389","volume":"5","author":[{"given":"Fadi","family":"Shbat","sequence":"first","affiliation":[{"name":"Department of Neurology, Ziv Medical Center","place":["Safed, Israel"]},{"name":"Azrieli Faculty of Medicine, Bar-Ilan University","place":["Safed, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Beiruti Wiegler","sequence":"additional","affiliation":[{"name":"Research Wing, Ziv Medical Center","place":["Safed, Israel"]},{"name":"Department of Internal Medicine B, Galilee Medical Centre","place":["Nahariyah, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najib","family":"Dally","sequence":"additional","affiliation":[{"name":"Azrieli Faculty of Medicine, Bar-Ilan University","place":["Safed, Israel"]},{"name":"Department of Hematology, Ziv Medical Center","place":["Safed, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Saad","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ziv Medical Center","place":["Safed, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saher","family":"Srour","sequence":"additional","affiliation":[{"name":"Department of Radiology, Ziv Medical Center","place":["Safed, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Eshel","sequence":"additional","affiliation":[{"name":"Hematology Laboratory, Ziv Medical Center","place":["Safed, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Sharabi Nov","sequence":"additional","affiliation":[{"name":"Research Wing, Ziv Medical Center","place":["Safed, Israel"]},{"name":"Tel-Hai University of Kiryat Shmona and the Galilee","place":["Tel Hai, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radi","family":"Shahien","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ziv Medical Center","place":["Safed, Israel"]},{"name":"Azrieli Faculty of Medicine, Bar-Ilan University","place":["Safed, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronen","family":"Leker","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hadassah-Hebrew University Medical Center","place":["Jerusalem, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naaem","family":"Simaan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ziv Medical Center","place":["Safed, Israel"]},{"name":"Azrieli Faculty of Medicine, Bar-Ilan University","place":["Safed, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"104877","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.104877","article-title":"High on-clopidogrel platelet reactivity in ischaemic stroke or transient ischaemic attack: systematic review and meta-analysis","volume":"29","author":"Alakbarzade","year":"2020","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1076029619875520","DOI":"10.1177\/1076029619875520","article-title":"The effect of CYP2C19 and nongenetic factors on clopidogrel responsiveness in the MENA region: a systematic review","volume":"25","author":"Ali","year":"2019","journal-title":"Clin. Appl. Thrombosis\/Hemostasis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/FPC.0000000000000469","article-title":"Effect of CYP2C19 genetic variants on bleeding and major adverse cardiovascular events in a cohort of Arab patients undergoing percutaneous coronary intervention and stent implantation","volume":"32","author":"Ali","year":"2022","journal-title":"Pharmacogene. Genom."},{"key":"B4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s43042-022-00313-w","article-title":"The efficacy of clopidogrel in preventing recurrent cardiovascular events among Arab population carrying different CYP2C19 mutations: systematic review and meta-analysis","volume":"23","author":"Alkattan","year":"2022","journal-title":"Egyptian J. Med. Human Gene."},{"key":"B5","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate","volume":"56","author":"Bonello","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1111\/j.1538-7836.2007.02775.x","article-title":"Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel","volume":"5","author":"Brandt","year":"2007","journal-title":"J. Thrombosis Haemostasis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1016\/j.jacc.2007.01.094","article-title":"Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis","volume":"49","author":"Buonamici","year":"2007","journal-title":"J. Am. College Cardiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/gim.2016.87","article-title":"Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)","volume":"19","author":"Caudle","year":"2017","journal-title":"Gene. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jns.2017.03.010","article-title":"High on treatment platelet reactivity to aspirin and clopidogrel in ischemic stroke: a systematic review and meta-analysis","volume":"376","author":"Fiolaki","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1540-8183.2011.00670.x","article-title":"Correlation between light transmission aggregometry, VerifyNow P2Y12, and VASP-P platelet reactivity assays following percutaneous coronary intervention","volume":"24","author":"Gaglia","year":"2011","journal-title":"J. Intervention. Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1538-7836.2007.02812.x","article-title":"The residual platelet aggregation after deployment of intracoronary stent (PREDICT) score","volume":"6","author":"Geisler","year":"2008","journal-title":"J. Thrombosis Haemostasis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1016\/j.jacc.2010.02.031","article-title":"Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement","volume":"55","author":"Hochholzer","year":"2010","journal-title":"J. Am. College Cardiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.ahj.2011.06.005","article-title":"Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy","volume":"162","author":"Hochholzer","year":"2011","journal-title":"Am. Heart J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1182\/blood-2006-04-013052","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects","volume":"108","author":"Hulot","year":"2006","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/nrcardio.2009.28","article-title":"Antiplatelet therapy: personalized medicine for clopidogrel resistance?","volume":"6","author":"Hulot","year":"2009","journal-title":"Nat. Rev. Cardiol."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-7196-1_24","author":"Hvas","year":"2017","journal-title":"Platelet Function Tests: Preanalytical Variables, Clinical Utility, Advantages, and Disadvantages. Hemostasis and Thrombosis: Methods and Protocols"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1111\/cts.12830","article-title":"CYP2C19 Allele frequencies in over 2.2 million direct-to-consumer genetics research participants and the potential implication for prescriptions in a large health system","volume":"13","author":"Ionova","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1161\/CIRCINTERVENTIONS.111.962555","article-title":"Effect of CYP2C19* 2 and* 3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin","volume":"4","author":"Jeong","year":"2011","journal-title":"Circulat. Cardiovasc. Intervent."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1161\/CIRCULATIONAHA.111.075242","article-title":"The role of platelet reactivity and genotype testing in the prevention of atherothrombotic cardiovascular events remains unproven","volume":"125","author":"Krishna","year":"2012","journal-title":"Circulation"},{"key":"B21","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/cpt.2526","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2C19 Genotype and clopidogrel therapy: 2022 update","volume":"112","author":"Lee","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.vph.2015.12.002","article-title":"The use of platelet reactivity testing in patients on antiplatelet therapy for prediction of bleeding events after cardiac surgery","volume":"77","author":"Leunissen","year":"2016","journal-title":"Vasc. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention, 2011 ACCF\/AHA guideline for coronary artery bypass graft surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA\/ACC guideline for the management of patients with non\u2013ST-elevation acute coronary syndromes, and 2014 ACC\/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery","volume":"134","author":"Levine","year":"2016","journal-title":"Circulation"},{"key":"B24","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrcardio.2014.104","article-title":"Expert consensus document: world heart federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI","volume":"11","author":"Levine","year":"2014","journal-title":"Nat. Rev. Cardiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1160\/TH11-03-0202","article-title":"Prevalence of poor biological response to clopidogrel","volume":"107","author":"Mallouk","year":"2012","journal-title":"Thrombosis Haemostasis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1161\/01.CIR.0000130846.46168.03","article-title":"Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction","volume":"109","author":"Matetzky","year":"2004","journal-title":"Circulation"},{"key":"B27","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000048046","article-title":"Preanalytical recommendations of the \u2018Groupe d'Etude sur l'Hemostase et la Thrombose'(GEHT) for venous blood testing in hemostasis laboratories","volume":"31","author":"Polack","year":"2001","journal-title":"Pathophysiol. Haemostasis Thrombosis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1161\/STR.0000000000000158","article-title":"2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"49","author":"Powers","year":"2018","journal-title":"Stroke"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e316","DOI":"10.1161\/STR.0000000000000513","article-title":"2026 Guideline for the early management of patients with acute ischemic stroke: a guideline from the American Heart Association\/American Stroke Association","volume":"57","author":"Prabhakaran","year":"2026","journal-title":"Stroke"},{"key":"B31","first-page":"194","article-title":"Spectral compensation for flow cytometry: visualization artifacts, limitations, and caveats","volume":"45","author":"Roederer","year":"2001","journal-title":"Cytometry J. Int. Soc. Analytical Cytol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1055\/s-0037-1615088","article-title":"European Working Group on Clinical Cell Analysis: consensus protocol for the flow cytometric characterisation of platelet function","volume":"79","author":"Schmitz","year":"1998","journal-title":"Thrombosis Haemostasis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/tpj.2011.5","article-title":"Identification of CYP2C19* 4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness","volume":"12","author":"Scott","year":"2012","journal-title":"Pharmacogenomics J."},{"key":"B34","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/clpt.2013.105","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update","volume":"94","author":"Scott","year":"2013","journal-title":"Clin. Pharmacol. Therapeutics"},{"key":"B35","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/clpt.2011.132","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450\u20132C19 (CYP2C19) genotype and clopidogrel therapy","volume":"90","author":"Scott","year":"2011","journal-title":"Clin. Pharmacol. Therapeutics"},{"key":"B36","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"B37","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1093\/eurheartj\/ehp041","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention","volume":"30","author":"Sibbing","year":"2009","journal-title":"European Heart J."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J. Am. College Cardiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1016\/j.jacc.2007.12.056","article-title":"Cytochrome P450 2C19 681G> A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents","volume":"51","author":"Trenk","year":"2008","journal-title":"J. Am. College Cardiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3390\/brainsci10030179","article-title":"Aspirin resistance affects medium-term recurrent vascular events after cerebrovascular incidents: a three-year follow-up study","volume":"10","author":"Wi\u015bniewski","year":"2020","journal-title":"Brain Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1515\/dmdi-2013-0069","article-title":"Pharmacogenetics in Jewish populations","volume":"29","author":"Yang","year":"2014","journal-title":"Drug Metabol. Drug Interact."},{"key":"B42","doi-asserted-by":"publisher","first-page":"19900","DOI":"10.18632\/oncotarget.24945","article-title":"Response to clopidogrel is associated with early neurological deterioration after acute ischemic stroke","volume":"9","author":"Yi","year":"2018","journal-title":"Oncotarget"},{"key":"B43","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/ane.13655","article-title":"High on-treatment platelet reactivity is associated with poor outcomes after ischemic stroke: a meta-analysis","volume":"146","author":"Zhou","year":"2022","journal-title":"Acta Neurol. Scand."}],"container-title":["Frontiers in Stroke"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fstro.2026.1908099\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T04:29:24Z","timestamp":1790569764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fstro.2026.1908099\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":43,"alternative-id":["10.3389\/fstro.2026.1908099"],"URL":"https:\/\/doi.org\/10.3389\/fstro.2026.1908099","relation":{},"ISSN":["2813-3056"],"issn-type":[{"value":"2813-3056","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"1908099"}}